These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

49 related articles for article (PubMed ID: 2968393)

  • 1. [Recourse to amniocentesis after the age of 38. Factors related to access to medical care].
    Czernichow P; Moirot H; Pierre M; Daniel P; Hemet J
    J Gynecol Obstet Biol Reprod (Paris); 1987; 16(6):729-36. PubMed ID: 2968393
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Periodic health examination, 1996 update: 1. Prenatal screening for and diagnosis of Down syndrome. Canadian Task Force on the Periodic Health Examination.
    Dick PT
    CMAJ; 1996 Feb; 154(4):465-79. PubMed ID: 8630836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Cost-benefit analysis of prenatal screening for trisomy 21 through analysis of HCG in maternal blood].
    Seror V; Moatti JP; Muller F; Le Galès C; Boué A
    Rev Epidemiol Sante Publique; 1993; 41(1):3-15. PubMed ID: 8465062
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How important is consent in maternal serum screening for Down syndrome in France? Information and consent evaluation in maternal serum screening for Down syndrome: a French study.
    Favre R; Duchange N; Vayssière C; Kohler M; Bouffard N; Hunsinger MC; Kohler A; Mager C; Neumann M; Vayssière C; Viville B; Hervé C; Moutel G
    Prenat Diagn; 2007 Mar; 27(3):197-205. PubMed ID: 17238219
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term trends for socio-economic differences in prenatal diagnosis of Down syndrome: diffusion of services or persistence of disparities?
    Khoshnood B; De Vigan C; Blondel B; Vodovar V; Cadio E; Goffinet F
    BJOG; 2008 Aug; 115(9):1087-95. PubMed ID: 18518869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health behaviour modelling for prenatal diagnosis in Australia: a geodemographic framework for health service utilisation and policy development.
    Muggli EE; McCloskey D; Halliday JL
    BMC Health Serv Res; 2006 Sep; 6():109. PubMed ID: 16945156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective evaluation of a second-trimester screening test for fetal Down syndrome using maternal serum alpha-fetoprotein, hCG, and unconjugated estriol.
    Cheng EY; Luthy DA; Zebelman AM; Williams MA; Lieppman RE; Hickok DE
    Obstet Gynecol; 1993 Jan; 81(1):72-7. PubMed ID: 7677967
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Controversy: systemic amniocentesis for women 38 years and more? Is it not premature to no longer accept performing amniocentesis on a patient age 38 years or more?].
    Sagot P
    Gynecol Obstet Fertil; 2000 Oct; 28(10):769-71. PubMed ID: 11270348
    [No Abstract]   [Full Text] [Related]  

  • 9. Screening advances and diagnostic choice: the problem of residual risk.
    Henry GP; Britt DW; Evans MI
    Fetal Diagn Ther; 2008; 23(4):308-15. PubMed ID: 18417998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Down syndrome: prenatal risk assessment and diagnosis.
    Newberger DS
    Am Fam Physician; 2000 Aug; 62(4):825-32, 837-8. PubMed ID: 10969860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factors affecting the decision regarding amniocentesis in women at genetic risk because of age 35 years or older.
    Vergani P; Locatelli A; Biffi A; Ciriello E; Zagarella A; Pezzullo JC; Ghidini A
    Prenat Diagn; 2002 Sep; 22(9):769-74. PubMed ID: 12224068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prenatal screening for trisomy 21 with maternal serum markers: information for decision-making in pregnant women].
    Seror V; Costet N; Ayme S
    J Gynecol Obstet Biol Reprod (Paris); 2000 Sep; 29(5):492-500. PubMed ID: 11011279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of maternal anxiety levels before and after amniocentesis.
    Ng CC; Lai FM; Yeo GS
    Singapore Med J; 2004 Aug; 45(8):370-4. PubMed ID: 15284930
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [How to improve the screening and diagnosis of fetal aneuploidy?].
    Ville Y
    Bull Acad Natl Med; 2005 Nov; 189(8):1773-84; discussion 1784-7. PubMed ID: 16737102
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Screening for Down's syndrome in the 2d trimester of pregnancy: initial results].
    Stejskal D
    Cesk Gynekol; 1993 Feb; 58(1):5-10. PubMed ID: 8319282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The utility assessment of Chinese pregnant women towards the birth of a baby with Down syndrome compared to a procedure-related miscarriage.
    Chan YM; Leung TN; Leung TY; Fung TY; Chan LW; Lau TK
    Prenat Diagn; 2006 Sep; 26(9):819-24. PubMed ID: 16832829
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of genetic counseling on decisions of pregnant women aged 35 years or over regarding amniocentesis in Turkey.
    Ilgin-Ruhi H; Yürür-Kutlay N; Tükün A; Bökesoy I
    Eur J Med Genet; 2005; 48(1):13-9. PubMed ID: 15953401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of trisomy 21 risk by serial determination of chorionic gonadotrophin hormone and alpha-fetoprotein: results of a national pilot study].
    Aymé S; Aurran Y; Chabal F; Gombert A; Loundou H; Montfort C; Sollier M; Silvestri A
    Contracept Fertil Sex; 1993 Feb; 21(2):133-43. PubMed ID: 7524931
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dental screening and referral of young children by pediatric primary care providers.
    dela Cruz GG; Rozier RG; Slade G
    Pediatrics; 2004 Nov; 114(5):e642-52. PubMed ID: 15520094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decisions about amniocentesis by advanced maternal age patients following maternal serum screening may not always correlate clinically with screening results: need for improvement in informed consent process.
    Marini T; Sullivan J; Naeem R
    Am J Med Genet; 2002 May; 109(3):171-5. PubMed ID: 11977174
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.